Patents Examined by Nianxiang Zou
  • Patent number: 11446373
    Abstract: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: September 20, 2022
    Assignee: International AIDS Vaccine Initiative, Inc.
    Inventors: Tom Jin, Eric I-Fu Tsao
  • Patent number: 11447528
    Abstract: The present invention is directed to a method for extracting hepatitis A virus (HAV) antigen from a cell culture as well as a use of a composition for extracting hepatitis A virus (HAV) antigen from a cell culture.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: September 20, 2022
    Inventor: Bertram Flehmig
  • Patent number: 11440945
    Abstract: Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: September 13, 2022
    Assignee: Fred Hutchinson Cancer Center
    Inventor: Matthias Stephan
  • Patent number: 11440948
    Abstract: This application relates generally to the production of modified, non-natural ?1-?2 domains of NKG2D ligands with attached polypeptides having specific target-binding properties, for example, antibodies or variable fragments of antibodies, that are selectively delivered to Chimeric Antigen Receptors (CARs) comprised of modified, non-natural NKG2D receptors on engineered mammalian cells. The targeting of surface-expressed molecules includes those of virus-infected cells that can then be attacked and ablated by engineered cells of the immunity system expressing CARs cognate to the modified, non-natural ?1-?2 domains of NKG2D ligands with attached polypeptides.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: September 13, 2022
    Assignees: Xyphos Biosciences Inc., THE J. DAVID GLADSTONE INSTITUTES
    Inventors: Kaman Kim, Nigel Killeen, Eytan Herzig, Warner Greene
  • Patent number: 11434525
    Abstract: Disclosed herein, inter alia, are compositions and methods of use thereof for interrogating a sample comprising a cell.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: September 6, 2022
    Assignee: SINGULAR GENOMICS SYSTEMS, INC.
    Inventor: Eli N. Glezer
  • Patent number: 11426458
    Abstract: The invention relates to a novel reconstitution composition, a pharmaceutical composition and kit of parts comprising said reconstitution composition. The invention further relates to a method of treatment using said pharmaceutical composition and/or the pharmaceutical composition for use as a medicament. Also provided is a method for reconstituting dried peptides and a method for preparing a pharmaceutical composition using the reconstitution composition of the invention.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: August 30, 2022
    Assignee: ISA PHARMACEUTICALS B.V.
    Inventor: Gwenn Eveline Mulder
  • Patent number: 11427618
    Abstract: The invention relates to a mutated HPV39 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV39 and HPV68, or HPV39, HPV68 and HPV70), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: August 30, 2022
    Assignees: XIAMEN UNIVERSITRY, XIAMEN INNOVAX BIOTECH, CO., LTD.
    Inventors: Shaowei Li, Daning Wang, Zhiping Wang, Xinlin Liu, Jun Zhang, Ningshao Xia
  • Patent number: 11421031
    Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: August 23, 2022
    Assignees: MacroGenics, Inc., Duke University
    Inventors: Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Liqin Liu, Jeffrey Lee Nordstrom, Barton F. Haynes, Guido Ferrari
  • Patent number: 11407790
    Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: August 9, 2022
    Assignee: HOOKIPA BIOTECH GMBH
    Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
  • Patent number: 11407806
    Abstract: Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill CMV or CMV-infected cells are also provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 9, 2022
    Assignee: Albert Einstein College of Medicine
    Inventors: Harris Goldstein, Steven C. Almo
  • Patent number: 11408026
    Abstract: Disclosed herein are methods for predicting susceptibility to an infection based on the observation of specific mutations in blood cells, as well as methods for treating or reducing susceptibility to an infection in a subject.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: August 9, 2022
    Assignee: LifeVault Bio, Inc.
    Inventors: Jonathon B. Hamilton, Salvatore G. Viscomi, Trevor J. Perry
  • Patent number: 11401306
    Abstract: Novel human papillomovirus immunogenic compositions and methods of use thereof are provided. The compositions comprise unique combinations of multi-epitope peptide sequences specifically selected and designed to be effectively processed and cross-presented to T-cells. The peptides utilized in the compositions display high levels of binding with HLA-supertypes. The immunogenic compositions are broadly applicable to large proportions of target populations. The compositions comprise adjuvants such as cationic lipids.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: August 2, 2022
    Assignee: PDS Biotechnology Corporation
    Inventors: Frank Bedu-Addo, Greg Conn, Martin Ward, Jerold Woodward
  • Patent number: 11390853
    Abstract: A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: July 19, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Jonathan Pokorski, Nicole Steinmetz, Parker Lee
  • Patent number: 11382972
    Abstract: The present disclosure relates to a composition comprising PIC for treatment of cancer. More particularly, the present disclosure discloses a composition for treatment of cancer comprising polyinosinic-polycytidylic acid, an antibiotic or polyamine compound, a positive ion, and optionally a virus, and the use thereof in manufacture of a medicament for treatment of cancer. No figure for publication.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: July 12, 2022
    Assignee: YISHENG BIOPHARMA (SINGAPORE) PTE LTD
    Inventor: Zhang Yi
  • Patent number: 11376318
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: July 5, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11351114
    Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: June 7, 2022
    Assignee: ENA THERAPEUTICS PTY LTD
    Inventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
  • Patent number: 11338032
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: May 24, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11331385
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: May 17, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11332721
    Abstract: Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: May 17, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Ursula J. Buchholz, Cindy Luongo
  • Patent number: 11324820
    Abstract: The present invention provides methods for the treatment of a subject having a Hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, using a combination of an RNAi agent that targets HBV and an HBV vaccine. It is disclosed a RNAi agent and an HBV vaccine for use in treatment of HBV infection, comprising sequentially administering to the subject having an HBV infection: a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent forms a double stranded region; b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, and a first HBV surface antigen (HBsAg) polypeptide; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, and/or a second HBsAg polypeptide, wherein the second HBcAg polypeptide, and/or the second HBsAg polypeptide, shares at least one epitope with at least one of the first HBcAg polypeptide, and/or the first HBsAg polypeptide.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: May 10, 2022
    Assignees: ALNYLAM PHARMACEUTICALS, INC., TECHNISCHE UNIVERSITÄT MÜNCHEN
    Inventors: Laura Sepp-Lorenzino, Ulrike Protzer, Thomas Michler